HC Wainwright Predicts Trevena’s Q1 Earnings (NASDAQ:TRVN)

Trevena, Inc. (NASDAQ:TRVN) – Research analysts at HC Wainwright issued their Q1 2025 EPS estimates for shares of Trevena in a research report issued on Thursday, November 14th. HC Wainwright analyst D. Tsao expects that the biopharmaceutical company will earn ($0.37) per share for the quarter. HC Wainwright has a “Neutral” rating and a $5.00 price objective on the stock. The consensus estimate for Trevena’s current full-year earnings is ($32.25) per share. HC Wainwright also issued estimates for Trevena’s Q2 2025 earnings at ($0.34) EPS, Q3 2025 earnings at ($0.37) EPS and Q4 2025 earnings at $0.18 EPS.

Separately, StockNews.com assumed coverage on Trevena in a research report on Monday, November 11th. They issued a “sell” rating for the company.

Trevena Stock Down 0.6 %

NASDAQ TRVN opened at $1.68 on Friday. The firm has a market cap of $1.44 million, a PE ratio of -0.04 and a beta of 1.08. Trevena has a 52 week low of $1.13 and a 52 week high of $19.23. The company has a 50 day moving average price of $3.05 and a 200 day moving average price of $5.61.

Trevena (NASDAQ:TRVN) last announced its quarterly earnings results on Thursday, November 7th. The biopharmaceutical company reported ($5.79) earnings per share (EPS) for the quarter. The firm had revenue of $0.28 million during the quarter.

Trevena Company Profile

Trevena, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel medicines for patients affected by central nervous system disorders. Its lead product candidates include OLINVYK (Oliceridine) injection, a G protein biased mu-opioid receptor (MOR) ligand for the management of moderate-to-severe acute pain; TRV250, a G protein biased delta-opioid receptor agonist for the treatment of acute migraine; TRV734, a small molecule G protein biased ligand of the MOR for the treatment of moderate-to-severe acute and chronic pain; and TRV045, a novel S1P modulator for managing chronic pain.